Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. Objective: The objective of this paper is to present efficacy and safety results in A...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2026-04-01
Ráidu:	The Journal of Prevention of Alzheimer's Disease
Fáttát:	Lecanemab Alzheimer’s disease Apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2274580726000312
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!